COVA1-16
An anti-SARS-CoV-2 monoclonal antibody.
General information
COVA1-16 is monoclonal antibody isolated from a COVID-19 convalescent patient for its affinity to Spike protein. The antibody neutralized SARS-CoV-2 in vitro. It was also observed to cross-neutralize SARS-CoV pseudovirus (Brouwer et al., 2020). COVA1-16 was observed to bind Spike RBD and to compete with ACE2 (Liu et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Spike protein Spike variant Protein factor In vitro Antibody Mixed substance |
Vero E6 cells; patient sera; SARS-CoV-2 live virus (WA1, B.1.1.7, and B.1.351 strains); (VSV) SARS-CoV-2 Spike pseudoviruses (various strain/mutations) | 49.96 | The antibody retains its activity against the B.1.351 strain in vitro. |
Mar/08/2021 |
|
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Spike protein Novel compound Protein factor In vitro Mechanism Antibody |
In vitro; patient sera | 47.73 | The antibody bound SARS-CoV-2 Spike and its RBD and neutralized the virus in vitro. It was also observed to cross-neutralize SARS-CoV pseudovirus. |
Jun/16/2020 |
|
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
Spike protein Crystallization Biophysical assay Protein factor In vitro Mechanism Antibody |
In vitro | 31.75 | COVA1-16 was observed to bind Spike RBD and to compete with ACE2. |
Nov/25/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
|
May/12/2021 |
